• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

FDA-TRACK

The list below provides information on FDA’s performance measures and projects as aligned to FDA strategic priorities and program offices. This list enables you to view charts of performance data and progress on important projects and programs.

To view completed FDA-TRACK performance measures and projects view the Archive Index

Filter








Results

Number of results: 8

ItemProgramOfficeStrategic PlanStrategic Goal/Area
1Percentage of INAD study submissions reviewed within the month that were acted on within 180 days after the submission dateCVMOffice of New Animal Drug EvaluationN/AN/A
2Percentage of INAD submissions consisting of protocols without substantial data reviewed and acted on within the month where the sponsor was notified of the Agency's decision on or before day 50CVMOffice of New Animal Drug EvaluationN/AN/A
3Percentage of manufacturing supplemental new animal drug applications and reactivations of such supplemental applications reviewed within the month that were acted on within 120 days after the submission dateCVMOffice of New Animal Drug EvaluationN/AN/A
4Percentage of non-administrative original ANADAs and reactivations of such applications completed on timeCVMOffice of New Animal Drug EvaluationN/AN/A
5Percentage of manufacturing supplemental ANADAs and reactivations of such supplemental applications completed on timeCVMOffice of New Animal Drug EvaluationN/AN/A
6Percentage of JINAD study submissions completed on timeCVMOffice of New Animal Drug EvaluationN/AN/A
7Percentage of JINAD submissions consisting of protocols without substanial data completed on timeCVMOffice of New Animal Drug EvaluationN/AN/A
8Percentage of administrative ANADAs (ANADAs submitted after all scientific decisions have been made in the JINAD process) completed on timeCVMOffice of New Animal Drug EvaluationN/AN/A

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information in the Archive Index may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.